Medivir hopes new CEO can kick-start clinical development
Swedish firm Medivir (Nasdaq: MVIR) has announced that Uli Hacksell will replace Christine Lind as chief executive, with immediate effect, just 18 months after she took up the position.
Earlier in the year Medivir was forced to delay until 2019 a pivotal trial program for lead compound remetinostat in cutaneous T-cell lymphoma (CTCL), with US FDA negotiations ongoing over the trial design.
Another setback for the firm came late last year when Johnson & Johnson (NYSE: JNJ) terminated its licence for hepatitis C drug Olysio/Sovriad (simeprevir), deciding there wasn’t enough profit in the deal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze